Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Monday, November 23, 2009, 10:23PM ET - U.S. Markets Closed. Dow Up 1.29% Nasdaq Up 1.40%
Evotec AG (EVTC)At 3:59PM ET: 6.11  Down 0.16 (2.55%)  
MORE ON EVTC
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
Evotec AG
Schnackenburgallee 114
Hamburg,  22525
Germany - Map
Phone: 49 40 560 810
Fax: 49 40 560 81222
Web Site: http://www.evotecoai.com

DETAILS 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Major
Full Time Employees:N/A

BUSINESS SUMMARY 
Evotec AG operates as a drug discovery and development company that focuses on small molecule therapeutics for diseases in the areas of neuroscience, pain, and inflammation. Its product portfolio includes EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer’s disease, pain, and depression; EVT 201, a partial positive allosteric modulator of the GABAA receptor for the treatment of insomnia; EVT 302, a MAO-B inhibitor in development for smoking cessation; a P2X7 antagonist for the treatment of inflammatory diseases; and a small molecule vanilloid receptor antagonist for the treatment of pain. The company’s proprietary late-stage preclinical research programs focuses on EVT 103, a back-up compound to EVT 101; H3 antagonists for the treatment of cognitive disorders and/or sleep, as well as antagonists for the purinergic receptor; and P2X3 for the treatment of pain. Evotec AG, through its research collaborations provide solutions that range from target to clinical development through a range of capabilities, including early-stage assay development and screening, fragment-based drug discovery, medicinal chemistry, and vivo pharmacology to the pharmaceutical and biotechnology industries. The company has collaborations with Boehringer Ingelheim, CHDI, Ono Pharmaceutical, and Novartis; and a strategic partnership with Roche for the development of compounds in treatment of resistant depression. Evotec AG, formerly known as EVOTEC BioSystems GmbH, was founded in 1993 and is headquartered in Hamburg, Germany.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on Evotec AG


    KEY EXECUTIVES 
     PayExercised
    Dr. Klaus Maleck , 37
    Chief Financial Officer and Member of the Management Board
    N/A N/A
    Dr. Mario Polywka Ph.D., 47
    Chief Operating Officer and Member of the Management Board
    N/A N/A
    Dr. Werner Lanthaler MBA/MPA, 40
    Chief Exec. Officer and Member of the Management Board
    N/A N/A
    Prof. Dr. Carsten M. H. Claussen ,
    Chief Exec. Officer of Evotec Technologies GmbH
    N/A N/A
    Dr. Michael Kelly Ph.D., MRSC, 55
    Pres of Site - California
    N/A N/A
    Dollar amounts are as of and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis